<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02246127</url>
  </required_header>
  <id_info>
    <org_study_id>GETNE1206</org_study_id>
    <secondary_id>2013-000726-66</secondary_id>
    <nct_id>NCT02246127</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET</brief_title>
  <acronym>SEQTOR</acronym>
  <official_title>Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Tumores Neuroendocrinos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Neuroendocrine Tumor Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantar Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Espanol de Tumores Neuroendocrinos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to elucidate which sequence of streptozotocin (STZ) based
      chemotherapy and the mammalian Target of Rapamycin (mTOR) inhibitor, everolimus, gives better
      results in terms of second Progression Free Survival (PFS) in well differentiated and
      advanced pancreatic NETs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STZ based chemotherapy, STZ-5FU, is the actual standard of care for advanced pancreatic
      Neuroendocrine tumours (pNETS) in the European Union. Everolimus has been recently approved
      for its use in advanced pNETs by the Food and Drug Administration (FDA) and in Europe by the
      European Medical Agency (EMA).

      A randomized study is needed to have a clear knowledge about the best sequence for its
      administration; this is, before or after palliative chemotherapy.

      There may or may not be any benefits from giving first each other treatment of the study. The
      information obtained from this study will help the physician improve the treatment and
      management of patients with advanced pNET.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Second Progression Free Survival (second PFS)</measure>
    <time_frame>Up to 140 +/- 8 weeks</time_frame>
    <description>PFS of Course 1 (PFS1) + interval between treatments + PFS of Course 2 (PFS2), where PFS1 represents progression free survival of Course 1 and PFS2 represents progression free survival of Course 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 30 days after 140 +/- 8 weeks</time_frame>
    <description>Number of adverse events, dose reductions, and total dose administered of each treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first progression</measure>
    <time_frame>Up to 44 weeks to everolimus and up 96 weeks for STZ-5-FU.</time_frame>
    <description>Time from the date of randomization to the date of first disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of incremental cost-efficacy (ICER)</measure>
    <time_frame>Up to 140+/-8 weeks</time_frame>
    <description>Ratio of the difference of costs incurred on by each treatment arm and the difference of second progression free survival at each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>Baseline and every 12 weeks up to 140+/-8 weeks</time_frame>
    <description>Rate of objective response (= Complete response (CR)+ Partial Response (PR)+Stable Disease (SD)) measured by RECIST criteria version 1.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Biochemical response</measure>
    <time_frame>Baseline and up to 4 weeks</time_frame>
    <description>Levels of Chromogranin A (CgA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second progression</measure>
    <time_frame>Up to 140+/-8 weeks</time_frame>
    <description>From the date of randomization to the date of second disease progression</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life Questionnaire (QLQ)</measure>
    <time_frame>Prior to initial dose on day 1 and after the last dose of each treatment</time_frame>
    <description>QLQ-C30 ver 3.0 QLQ specific for gastrointestinal neuroendocrine tumors (GINET21)</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 140+/-8 weeks</time_frame>
    <description>From the date of randomization until death from any cause.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Sequence A, drug: everolimus first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus (10mg/daily, oral) followed by STZ-5FU (injection/infusion; Moertel or Uppsala regime).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B, drug: STZ - 5FU first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STZ-5FU (injection/infusion; Moertel or Uppsala regime) followed by Everolimus (10 mg/ daily, oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Everolimus</intervention_name>
    <description>10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Sequence A, drug: everolimus first</arm_group_label>
    <arm_group_label>Sequence B, drug: STZ - 5FU first</arm_group_label>
    <other_name>Afinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STZ-5FU</intervention_name>
    <description>0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).
Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Sequence A, drug: everolimus first</arm_group_label>
    <arm_group_label>Sequence B, drug: STZ - 5FU first</arm_group_label>
    <other_name>STZ based Chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven diagnosis of unresectable or metastatic, advanced pancreatic
             NET.

          -  Documented confirmation of pancreatic NET G1 or G2 as per European Neuroendocrine
             Society (ENETS) classification system.

          -  Patients from whom a paraffin-embedded primary tumour or metastasis block is available
             and to be sent by Courier.

          -  Before study inclusion, patients must show progressive disease documented by radiology
             12 months prior to study inclusion. Treatment naive patients can be also included if
             the patient needs active treatment with either chemotherapy or everolimus.

          -  Presence of measurable disease as per Response Evaluation Criteria in Solid Tumors
             (RECIST) criteria 1.0, documented by a Triphasic Computed Tomography (CT) scan or
             multiphase MRI radiological assessment.

          -  Previous treatment with somatostatin (SS) analogues is allowed. Only those patients
             with active functioning syndrome at entry can continue with SS analogues during the
             study.

          -  Adequate bone marrow and renal functions, and serum fasting cholesterol

          -  Women with child-bearing potential must have a negative serum pregnancy test.

          -  Written Informed Consent obtained according to local regulations

        Exclusion Criteria:

          -  Previous treatment with chemotherapy and/or mTOR inhibitors or tyrosine kinase
             inhibitors.

          -  Immune therapy or radiation therapy within 4 weeks prior to the patient entering the
             study.

          -  Hepatic artery embolization within the last 6 months (1 month if there are other sites
             of measurable disease), or cryoablation/radiofrequency ablation of hepatic metastasis
             within 2 months of enrolment.

          -  Previous treatment with Peptide-Receptor Radionuclide Therapy (PRRT) within the last 6
             months and/or without progression following PRRT.

          -  Uncontrolled diabetes mellitus.

          -  Any severe and/or uncontrolled medical conditions.

          -  Treatment with potent inhibitors or inducers of Cytochrome P450 3A4 (CYP3A) isoenzyme
             within 5 days immediately before the start of treatment.

          -  Patients on chronic treatment with corticosteroids or any other immunosuppressive
             agent.

          -  Patients known to be HIV seropositive.

          -  Known intolerance or hypersensitivity to everolimus or its excipients or other
             rapamycin analogues. Patients with rare hereditary problems of galactose intolerance,
             Lapp lactase deficiency or glucose-galactose malabsorption should not take this
             medicinal product.

          -  Known intolerance or hypersensitivity to 5FU or STZ or its excipients (notice that
             this criterion includes patients with known deficit of dihydropyrimidine dehydrogenase
             deficiency -DPD).

          -  Pregnant, lactating women or fertile adults not using effective birth control methods.

          -  For administrative matters (insurance) patients ≥ 95 are not allowed during the trial.

        Only those patients coming from the hospital pool will be included in SEQTOR trial (e.g.
        persons detained in an institution as a result of an official or court order are excluded).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>94 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salazar Ramon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Catalán de Oncologia, ICO-Hospitalet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Vidal, BSc, PhD</last_name>
    <phone>+34932134478</phone>
    <email>cvidal@needsamdaims.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valentin Navarro, BStatistics</last_name>
    <phone>:+34 93 260 78 22</phone>
    <email>vnavarro@iconcologia.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus Aarhus University Hospital NET Centre (AUH-NET)</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Ladekarl</last_name>
    </contact>
    <investigator>
      <last_name>Morten Ladekarl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet NET CoE, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Peter Knigge</last_name>
    </contact>
    <investigator>
      <last_name>Ulrich Peter Knigge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCG / University of Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Derk Jan de Groot</last_name>
    </contact>
    <investigator>
      <last_name>Derk Jan de groot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith de Vos-Geelen</last_name>
    </contact>
    <investigator>
      <last_name>Judith de Vos-Geelen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lene Vestermark</last_name>
    </contact>
    <investigator>
      <last_name>Lene Vestermark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brest Hopital Augustin Morvan, Institut de Cancero-Hemato</name>
      <address>
        <city>Brest</city>
        <state>Brest Cedex</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe Metges</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Philippe Metges</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clichy Neuroendocrine Tumor (NET) Center Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <state>Clichy Cedex</state>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Ruszniewski</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Ruszniewski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave-Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Paris</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Baudin</last_name>
    </contact>
    <investigator>
      <last_name>Eric Baudin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <state>Strasbourg Cedex</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard Goichot</last_name>
    </contact>
    <investigator>
      <last_name>Bernard Goichot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UTTIOM Unité Transversale de Thérapeutiques Innovantes en Oncologie Médicale CHU Angers</name>
      <address>
        <city>Anger</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francois-Xavier Caroli-Bosc</last_name>
    </contact>
    <investigator>
      <last_name>Francois-Xavier Caroli-Bosc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux Hôpital Saint-André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Smith</last_name>
    </contact>
    <investigator>
      <last_name>Denis Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Walter</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Walter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Francois Seitz</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Francois Seitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bad Berka ChA Klinik für Innere Medizin</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Hörsch</last_name>
    </contact>
    <investigator>
      <last_name>Dieter Hörsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Berlin Charité Universitätsmedizin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Ulrich Pape</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UKM Facharzt für Innere Medizin Gastroenterologie, Onkologische Gastroenterologie (DGVS)</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastian Krug</last_name>
    </contact>
    <investigator>
      <last_name>Sebastian Krug</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik , Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joerg Schrader</last_name>
    </contact>
    <investigator>
      <last_name>Joerg Schrader</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Köln Universitätsklinikum Köln (AöR)</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgit Cremer</last_name>
    </contact>
    <investigator>
      <last_name>Birgit Cremer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magdeburg Universitätsklinikum Magdeburg A. ö. R</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Malfertheiner</last_name>
    </contact>
    <investigator>
      <last_name>Peter Malfertheiner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mainz Universitätsmedizin</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathias Weber</last_name>
    </contact>
    <investigator>
      <last_name>Mathias Weber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marburg Universitätsklinikum Giessen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Rinke</last_name>
    </contact>
    <investigator>
      <last_name>Anja Rinke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM) at the University of Munich</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Josef Auernhammer</last_name>
    </contact>
    <investigator>
      <last_name>Christoph Josef Auernhammer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizin II am Klinik und Poliklinik rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander von Werder</last_name>
    </contact>
    <investigator>
      <last_name>Alexander von Werder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia- IRCCS</name>
      <address>
        <city>Milano</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Carnaghi</last_name>
    </contact>
    <investigator>
      <last_name>Carlo Carnaghi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori (Fondazione G Pascale)</name>
      <address>
        <city>Napoli</city>
        <state>Naples</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Tafuto</last_name>
    </contact>
    <investigator>
      <last_name>Salvatore Tafuto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz-Josef Klümpen</last_name>
    </contact>
    <investigator>
      <last_name>Heinz-Josef Klümpen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Jimenez Fonseca</last_name>
    </contact>
    <investigator>
      <last_name>Paula Jimenez Fonseca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luis Manzano</last_name>
    </contact>
    <investigator>
      <last_name>Jose Luis Manzano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Catalán de Oncología de Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Teule</last_name>
    </contact>
    <investigator>
      <last_name>Alexander Teule</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marta Martin</last_name>
    </contact>
    <investigator>
      <last_name>Marta Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaume Capdevila</last_name>
    </contact>
    <investigator>
      <last_name>Jaume Capdevila</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocío García-Carbonero</last_name>
    </contact>
    <investigator>
      <last_name>Rocío García-Carbonero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCU Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Isabel Sevilla</last_name>
    </contact>
    <investigator>
      <last_name>Maria Isabel Sevilla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Benavent</last_name>
    </contact>
    <investigator>
      <last_name>Marta Benavent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbro Eriksson</last_name>
    </contact>
    <investigator>
      <last_name>Barbro Eriksson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West of Scotland Cancer Centre Gartnavel General Hospital</name>
      <address>
        <city>Beatson</city>
        <state>Glasgow</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Simon Reed</last_name>
    </contact>
    <investigator>
      <last_name>Nicholas Simon Reed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2014</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced pNET</keyword>
  <keyword>everolimus</keyword>
  <keyword>STZ-5FU</keyword>
  <keyword>treatment sequence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>As per GETNE guidelines and local laws</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

